Kaposi sarcoma
Drug research and approvals for kaposi sarcoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 25 studies of kaposi sarcoma are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and FDA has 1 approved and 2 open orphan designations naming it.
- Recruiting worldwide: 25
- Trials authorized in Canada: 0
- FDA orphan approvals: 1
- EU medicines: 0
- New Approaches for the Diagnosis of Lymphoma and Multicentric Castleman DiseaseNCT07793006 · Not applicable · Indiana University · starts Mar 17, 2025
- Nirogacestat in Patients With Kaposi SarcomaNCT07539454 · Phase 2 · AIDS Malignancy Consortium · starts Oct 13, 2026
- Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma in Participants With HIV and…NCT07308886 · Phase 2 · National Cancer Institute (NCI) · starts Apr 8, 2026
- Sequential Infusion of CD146-Targeted and HER2-Targeted CAR T Cells in Patients With Advanced SarcomasNCT07066982 · Phase 1 / Phase 2 · Essen Biotech · starts May 29, 2025
- Precision Imaging to Evaluate Kaposi SarcomaNCT06898203 · Not applicable · Washington University School of Medicine · starts Apr 10, 2026
- Precision Imaging to Evaluate Kaposi Sarcoma (PRIME-KS): A Device Feasibility TrialNCT06751355 · Not reported · Washington University School of Medicine · starts Feb 25, 2025
- Propranolol for the Treatment of Kaposi Sarcoma in AdultsNCT06445166 · Phase 2 · Washington University School of Medicine · starts Aug 20, 2025
- Natural History Study of Kaposi SarcomaNCT06375122 · Not reported · National Cancer Institute (NCI) · starts May 15, 2024
- The Effects of Sirolimus in Patients With Dilated Cardiomyopathy Infected With Kaposi Sarcoma-associated VirusNCT06236022 · Phase 4 · Tongji Hospital · starts Jan 1, 2024
Approved 4
- DoxorubicinDNA topoisomerase II alpha inhibitor
- PaclitaxelTubulin inhibitor
- Interferon alfa-2bInterferon alpha/beta receptor agonist
- AlitretinoinRetinoid receptor agonist
Phase 3 3
- BleomycinDNA inhibitor
- VincristineTubulin inhibitor
- DaunorubicinDNA topoisomerase II alpha inhibitor
Phase 2 12 of 21
- PomalidomideCRL4(CRBN) E3 ubiquitin ligase inhibitor
- BevacizumabVascular endothelial growth factor A inhibitor
- IndinavirHuman immunodeficiency virus type 1 protease inhibitor
- PembrolizumabProgrammed cell death protein 1 inhibitor
- SEPHB4-HSAEphrin-B2 inhibitor
- AbacavirHuman immunodeficiency virus type 1 reverse transcriptase inhibitor
- EverolimusFK506-binding protein 1A inhibitor
- LamivudineHuman immunodeficiency virus type 1 reverse transcriptase inhibitor
- MaravirocC-C chemokine receptor type 5 antagonist
- PropranololBeta-1 adrenergic receptor antagonist
- RitonavirHuman immunodeficiency virus type 1 protease inhibitor
- SunitinibMacrophage colony stimulating factor receptor inhibitor
Phase 1 or earlier 9
- LenalidomideCRL4(CRBN) E3 ubiquitin ligase inhibitor
- SorafenibSerine/threonine-protein kinase RAF inhibitor
- SelumetinibDual specificity mitogen-activated protein kinase kinase 1 inhibitor
- AbemaciclibCyclin-dependent kinase 4 inhibitor
- SGN-30Tumor necrosis factor receptor superfamily member 8 agonist
- Bintrafusp alfaProgrammed cell death 1 ligand 1 binding agent
- Sivifene
- Immunocytokine NHS-IL12
- Interleukin-12 human recombinant
How its trials ended
159 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 25 whose ending is known, 32% met their primary endpoint, 8% missed it and 60% stopped early.
- Completed, result not reported9459%
- Ongoing3321%
- Met its primary endpoint85%
- Status unknown74%
- Stopped: enrollment or feasibility53%
- Stopped: other or unclear53%
- Missed its primary endpoint21%
- Stopped: sponsor or business decision21%
- Stopped: lack of efficacy11%
- Stopped: safety11%
- Stopped: funding11%
| May 14, 2020 | Pomalyst®POMALYST (pomalidomide) is indicated for the treatment of adult patients with AIDS-related Kaposi sarcoma (KS) after failure of highly… | Celgene Corporation | Approved |
| Jan 12, 2021 | AlitretinoinTreatment of systemic (non-cutaneous) kaposi sarcoma | Galephar Pharmaceutical Research, Inc. | Designated |
| Sep 20, 2012 | H-Leu-Pro-Pro-Ser-Arg-OHTreatment of Kaposi sarcoma | Immuno Tech, Inc. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA